jps holding sc

Proprietary & Confidential;

JPSHolding SCServing Life Sciences Industries Since 1993

Proprietary & Confidential;

Core Business Portfolio Management Products evaluation Products development Licensing-In and Out Expert Reports Regulatory dossiers development and

submission: medicines, food supplements, dietary foods for special medical purposes.

Drug Delivery Technology

Proprietary & Confidential;

Licensing-in (for Clients)

Paediatics drugs, medical food, food supplements

BCAA

Proprietary & Confidential;

Licensing-out AS 21: skin ulcers treatment (medical

device) AS 22: mucitis treatment (medical

device) Dualsetron®: Chemotherapy-Induced

Nausea and Vomiting treatment (Internal)

Biridone®: Bipolar disorders (Internal) Thixans® technology: thixotropic

formulation

MEDICAL For of skin injuries

AS-21

CE Authorization 0459

Proprietary & Confidential;

Proprietary & Confidential;

FIRST SPECIFIC TREATMENT AGAINST:

Bedsore (Superficial & Deep) Superficial & Deep Skin Injuries Pressure sore/Pressure ulcers Decubitus ulcers Diabetic skin ulcers

A NEW TRIPLE ACTION APPROACH

Proprietary & Confidential;

SALES New product: CE marking in August 2010 2 Trial launch in Finland January 2010 Sales Finland (Aktisor): 32 000 Launched in Austria 2010 – 10 000 units Israel- February 2011 Planned: Egypt, Middle East countries, India, Irak,

S. Africa, Australia,

Proprietary & Confidential;

AS 22 Specific treatment for Chemotherapy Induced oral mucositis (CIOM)

Proprietary & Confidential;

AS 22 OROCHEM® Mucitis following hemo and radiotherapy Colorless, odorless, sweet, viscous, 100

natural solution. Easy to apply, no side effects. Registered as a Class IIa medical device

due to its mechanical effects.

Proprietary & Confidential;

Dualsetron® Fixed-Dose combination for

Chemotherapy-Induced Nausea And Vomiting treatment.

Proprietary & Confidential;

Dualsetron

Proprietary & Confidential;

Biridone® Bipolar-disorders treament Patented formulation for once-day-

treatment

Proprietary & Confidential;

Development Status:

CR formulation completed Analytical development completed Stability studies Pilot Pk study completed MBDD protocol completed

Proprietary and Confidential: deNovelda Farmaceutica

THIXANS®: THE THIXOTROPIC DEVICE

Pure or formulated active ingredient or microparticulate dosage forms (pellets, beadlets, spheroids etc..) manufactured by usual pharmaceutical technologies are embedded into a Thixotropic Cushion ® either extemporaneously or regenerated by the microparticule itself.

Proprietary and Confidential: deNovelda Farmaceutica

DiffusionCoating

DiffusionCoating

MicrospheresMicrospheres

Thixotropic Cushion®Thixotropic Cushion®

EncapsulationEncapsulation

TechnologiesTechnologies

Thixotropic coatingThixotropic coating

DrugDrug